Pharmacy

Top Medical News
Omalizumab helps reduce allergic reactions to foods in kids
Jairia Dela Cruz, 8 hours ago
In young children with multiple food allergies, a treatment course with omalizumab appears to increase tolerance to peanuts and other common food allergens.
Which factors predict mortality in advanced HCC?
9 hours ago
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
Stephen Padilla, 10 hours ago
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Low-dose epinephrine does not reduce blood loss during TURP but lowers hypotension risk
16 hours ago
In patients undergoing transurethral resection of prostate (TURP), treatment with low-dose epinephrine falls short of reducing blood loss during the operation but appears to minimize the incidence of hypotension, as reported in a study.
Major adverse kidney events common among young people undergoing CKRT
Yesterday
Almost two-thirds of youths undergoing continuous kidney replacement therapy (CKRT) have major adverse kidney events 90 days after CKRT initiation (MAKE-90), with risk factors including cardiac comorbidity, time to CKRT initiation, and liberation patterns, according to a study.
Team approach to care optimizes bariatric surgery outcomes
Jairia Dela Cruz, Yesterday
Applying the collaborative prescribing (CP) practice framework in the care of patients who have undergone bariatric surgery in Singapore is viable and helps the patients achieve the best possible outcomes, reports a research team from the Singapore General Hospital.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Stephen Padilla, Yesterday
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
Special Reports
Nicorette® QuickMist Launch Symposium
19 Jan 2024
During the launch of Nicorette® QuickMist at the Kuala Lumpur Nicotine Addiction International Conference (KLNAC) 2023, a panel of distinguished experts led the discussion on the role of Nicotine Replacement Therapy (NRT) on smoking cessation management. The panel comprised of notable experts, including Professor Chris Bullen (New Zealand), Associate Professor Dr Amer Siddiq bin Amer Nordin (Malaysia), Dr Philip Tønnesen (Denmark) and Professor Philip Eng (Singapore).
COVID-19, nirmatrelvir, ritonavir, mRNA vaccine, Omicron, COPD, CDC, WHO
Dr. Chan Kwok Wai Adrian, Prof. Yang Kuang-Yao, 10 Jan 2024
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Navigating invasive fungal infections in unconventional hosts — insights and strategies
Assoc Prof. Carolina García-Vidal, Dr. Jasmine Chung, 06 Jan 2024

At a recent symposium organized by Pfizer, in collaboration with the Society of Infectious Disease Singapore, A/Prof Carolina García-Vidal, Senior Specialist, Infectious Diseases Department at Hospital Clínic de Barcelona, Spain, shared valuable insights on managing invasive fungal infections (IFIs) in nontraditional hosts. The session was chaired by Dr Jasmine Chung, Senior Consultant and Director of the Antimicrobial Stewardship Unit, Singapore General Hospital.

Product Highlight - MENQUADFI
28 Dec 2023
Meningococcal group A, C, W & Y conjugate vaccine 0.5 mL solution for injection
Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore
06 Dec 2023
In a pioneering effort, the Headache Society of Singapore (HSS) has released the first edition of consensus guidelines focusing on the approach to headache disorders and management of migraine. Amid a rapidly growing array of therapeutic options, standardizing treatment approaches is crucial. These guidelines provide a pivotal resource for healthcare professionals navigating the complex landscape of headache disorders, with a special focus on migraine management in adults.
A closer look at ceftazidime-avibactam in real-world settings
07 Nov 2023

Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.

Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.

New study unlocks rimegepant benefits for acute migraine
06 Nov 2023

A landmark study conducted in China and South Korea has demonstrated the effectiveness and safety of rimegepant – a groundbreaking orally administered calcitonin gene-related peptide (CGRP) antagonist – for the acute treatment of migraine among adults. [Lancet Neurol 2023;22:476-484] This phase III, double-blind, randomized, placebo-controlled trial marks the first clinical study of a gepant for migraine in China and South Korea, offering promising insights into migraine management.

Conference Reports
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Stephen Padilla, 29 Feb 2024
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
Audrey Abella, 29 Feb 2024
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.
Adjuvant pembrolizumab holds promise in bladder cancer
Audrey Abella, 28 Feb 2024
The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.
KEYNOTE-564: Adjuvant pembrolizumab ups survival in kidney cancer
Elaine Soliven, 28 Feb 2024

Adjuvant treatment with pembrolizumab has significantly improved overall survival (OS) in patients with clear cell renal cell carcinoma (RCC) who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial presented at ASCO GU 2024.

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit
Jairia Dela Cruz, 25 Feb 2024
Combination treatment with durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) leads to higher rates of pathologic complete response (pCR) in patients with resectable gastric cancer (GC) or gastroesophageal junction cancer (GEJC), with the benefit universally observed regardless of geographic location, according to the subgroup analysis of the phase III MATTERHORN study.
Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer
Stephen Padilla, 24 Feb 2024
First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.
Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates
Audrey Abella, 23 Feb 2024
In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.